Editorial review: osvilt.com Editorial Team
Last reviewed: July 16, 2026
How we reviewed this page: We checked current regulator guidance, product information and clinical guidance. Brand formulas and approvals vary by country, so readers should verify the exact local label.
This article is educational and does not replace individual care. Read our Medical Review Policy and Medical Disclaimer.
Regulon and Rigevidon are combined oral contraceptives (COCs), but they are not identical. Common Regulon 150/30 contains 30 micrograms ethinylestradiol plus 150 micrograms desogestrel. Rigevidon 30/150 contains 30 micrograms ethinylestradiol plus 150 micrograms levonorgestrel. Always confirm the exact pack in your country.
Bottom line: both can provide effective contraception when used correctly. Levonorgestrel-containing COCs such as Rigevidon have a lower estimated venous blood-clot risk than desogestrel-containing COCs such as Regulon, but individual contraindications, side effects and preferences determine the right method.
Regulon vs Rigevidon at a glance
| Point | Regulon 150/30 | Rigevidon 30/150 |
|---|---|---|
| Estrogen | Ethinylestradiol 30 micrograms | Ethinylestradiol 30 micrograms |
| Progestogen | Desogestrel 150 micrograms | Levonorgestrel 150 micrograms |
| VTE estimate | About 9-12 per 10,000 users per year for desogestrel-containing CHCs. | About 5-7 per 10,000 users per year for levonorgestrel-containing CHCs. |
| STI protection | No | No |
| Best choice | The safest acceptable method after reviewing blood pressure, migraine, smoking, clot history, medicines and preferences. | |
Putting blood-clot risk in context
The EMA estimates about 2 venous thromboembolisms (VTEs) per 10,000 women per year among those not using a CHC and not pregnant, about 5-7 with levonorgestrel-containing CHCs and about 9-12 with desogestrel-containing CHCs. These are population estimates, not a prediction for one person. Pregnancy and the postpartum period also carry clot risk.
Risk changes over time and is affected by prior VTE, thrombophilia, smoking, age, migraine with aura, high blood pressure, obesity combined with other factors, major surgery/immobility, postpartum status and some medical conditions. Blood pressure should be checked before starting a CHC.
How clinicians think about the choice
- Start with eligibility: some people should avoid estrogen-containing contraception altogether.
- Then consider risk: when a CHC is suitable, a levonorgestrel option may be preferred when minimizing VTE risk is a priority.
- Then consider experience: bleeding pattern, headaches, mood, acne and other effects can influence continuation, but do not erase contraindications.
- Keep the decision noncoercive: pills, progestogen-only methods, implants, IUDs and barrier methods have different benefits and tradeoffs.
Do not switch packs in the middle of a cycle or improvise after missed pills. Follow the leaflet for the exact product and obtain advice when instructions are unclear, because backup contraception or emergency contraception may be needed.
July 2026 desogestrel safety update
In July 2026, the EMA’s Pharmacovigilance Risk Assessment Committee announced new measures after finding a small increased risk of meningioma with current prolonged use (more than one year) of desogestrel- or etonogestrel-containing contraceptives. The overall likelihood remains very low: EMA estimated one additional meningioma for every 67,300 users.
EMA states that desogestrel-containing medicines are contraindicated in people with a current or previous meningioma. Product information is being updated. Users should not stop contraception abruptly based on a headline; contact the prescriber to review alternatives and maintain pregnancy protection.
When to seek urgent care
Get urgent help for one-sided leg swelling or pain, sudden shortness of breath, chest pain, coughing blood, sudden severe headache, new weakness/numbness, speech or vision change, or collapse. Arrange prompt review for new persistent/worsening headaches, seizures, hearing/vision changes, loss of smell or limb weakness, particularly with prolonged desogestrel use.
FAQ
Is Rigevidon safer than Regulon?
Its levonorgestrel component is associated with a lower population VTE estimate than desogestrel, but personal medical eligibility is more important than a brand ranking.
Do these pills protect against sexually transmitted infections?
No. Condoms reduce STI transmission risk and can be used alongside either pill.
Should I stop Regulon because of the 2026 meningioma update?
Do not create a gap in contraception on your own. Contact the prescriber promptly if you have a current/past meningioma or concerning neurological symptoms; otherwise arrange a routine risk review.
Sources reviewed
We prioritize regulators, official product information and clinical guidelines. External sources were checked on July 16, 2026.
- EMA PRAC meeting highlights, July 2026: desogestrel and meningioma
- EMA: Combined hormonal contraceptives and VTE risk
- CDC: U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
- CDC: Combined hormonal contraceptive practice recommendations
- Rigevidon patient information leaflet
- Saudi FDA drug information: Regulon 150/30
